Literature DB >> 7756494

Diminished activity of ceftizoxime in comparison to cefotaxime and ceftriaxone against Streptococcus pneumoniae.

D W Haas1, C W Stratton, J P Griffin, L Weeks, S C Alls.   

Abstract

Previous reports documenting the essentially identical spectra of activity of ceftizoxime, cefotaxime, and ceftriaxone prompted our hospital formulary committee to replace the latter two drugs with ceftizoxime on the basis of cost differences. However, we subsequently observed that every one of 60 isolates of Streptococcus pneumoniae tested was less susceptible to ceftizoxime than to either cefotaxime or ceftriaxone. The difference between minimal inhibitory concentrations (MICs) was greatest for strains moderately or fully resistant to penicillin, which at our institution represent approximately 32% of all isolates of S. pneumoniae. Ten isolates with cefotaxime and ceftriaxone MICs of 2.0-6.0 micrograms/mL had ceftizoxime MICs of > or = 256 micrograms/mL. Time-kill kinetic studies assessing bactericidal activity confirmed the diminished activity of ceftizoxime against penicillin-resistant isolates of S. pneumoniae. Ceftizoxime should not be used to treat proven or suspected pneumococcal infection in areas where resistance to penicillin is prevalent.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7756494     DOI: 10.1093/clinids/20.3.671

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

1.  Emergence in france of multiple clones of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxicillin.

Authors:  C Doit; C Loukil; F Fitoussi; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

2.  Bactericidal activities of ceftizoxime and cefotaxime against Streptococcus pneumoniae.

Authors:  K B Waites; T Rivers
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

3.  In vitro activity of ceftizoxime, ceftazidime, cefuroxime, ceftriaxone, cefotaxime, and penicillin against Streptococcus pneumoniae as determined by three quantitative methods.

Authors:  A L Barry; S D Brown; P C Fuchs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

4.  Antimicrobial susceptibilities and serotypes of invasive Streptococcus pneumoniae strains in Switzerland.

Authors:  J Wüst; E Huf; F H Kayser
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

5.  Comparative serum bactericidal activities of ceftizoxime and cefotaxime against intermediately penicillin-resistant Streptococcus pneumoniae.

Authors:  K B Patel; D P Nicolau; C H Nightingale; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 6.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

7.  Antimicrobial prospect of newly synthesized 1,3-thiazole derivatives.

Authors:  Bassem Sadek; Moawia Mohammad Al-Tabakha; Khairi Mustafa Salem Fahelelbom
Journal:  Molecules       Date:  2011-11-09       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.